Physicians’ Education Resource in conjunction with the California Cancer Consortium
Last Modified: May 6, 2010
Conference Dates: May 14-16, 2010
Conference Location: Pasadena
Sponsoring Group: Physicians’ Education Resource in conjunction with the California Cancer Consortium
Conference Web Page URL: http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/543
Topics Covered: At the conclusion of this conference, you should be able to: Assess the prognostic and predictive value of molecular biomarkers for patients with cancer Discuss the role of patient/tumor characteristics in designing personalized therapy for patients with cancer Select novel targeted therapies that optimize efficacy and minimize side effects based on tumor characteristics Evaluate the efficacy and safety of novel agents in the treatment of patients with cancer based on the results of recent clinical trials Evaluate clinical trial and translational methodologies for proper use in the clinical investigation decision-making process Describe the necessary elements for an effective clinical trial in patients with cancer
Conference Objectives: Designed to provide participants with updates on cutting-edge clinical trial design and therapeutic strategies for a variety of tumor types, including lung, breast, gastrointestinal, hematologic, gynecologic, and genitourinary cancers.
Who Should Attend: medical, surgical, and radiation oncologists and hematologists, Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to attend.
Conference Agenda: Please see our website @ www.cancerlearning.com for a three day Agenda
Registration Information: Promo Code CCCPWeb, it is case sensitive. This is for $25.00 off of the registration fee.
Conference Fees: Please see our website for current pricing
Continuing Education: Yes
Feb 3, 2011 - A T-cell receptor-based gene therapy directed against NY-ESO-1 cancer/testis antigen may represent a new therapeutic approach for patients suffering from melanoma and synovial cell sarcoma, according to a study published online Jan. 31 in the Journal of Clinical Oncology.